STOCK TITAN

PTC Therapeutics (PTCT) grants RSUs and stock options to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026. Grants included 4,000 restricted stock units vesting in three equal annual installments from July 28, 2027, and 2,000 restricted stock units vesting on January 2, 2027. She was also granted stock options for 3,475 and 1,738 shares of common stock at an exercise price of $75.39 per share, vesting over 36 and six equal monthly installments respectively, with both option grants expiring on July 27, 2036.

Positive

  • None.

Negative

  • None.
Insider Sollie-Zetlmayer Hege Elisabeth
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F3 3,475 $0.00 $0.00
Grant/Award Stock Option (Right to Buy) F4 1,738 $0.00 $0.00
Grant/Award Common Stock F1 4,000 $0.00 $0.00
Grant/Award Common Stock F2 2,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 5,213 shares (Direct); Common Stock — 52,526 shares (Direct)
Footnotes (4)
  1. F1. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027.
  2. F2. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027.
  3. F3. This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026.
  4. F4. This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026.
RSU Grant 1 4,000 shares Restricted stock units vesting in three equal annual installments from July 28, 2027
RSU Grant 2 2,000 shares Restricted stock units vesting on January 2, 2027
Stock Option Grant 1 3,475 shares at $75.39 Option vesting over 36 equal monthly installments from August 28, 2026; expires July 27, 2036
Stock Option Grant 2 1,738 shares at $75.39 Option vesting over six equal monthly installments from August 2, 2026; expires July 27, 2036
Transaction Date July 28, 2026 Grant date for all reported RSU and stock option awards
Restricted stock units financial
"Restricted stock units granted on July 28, 2026, with the shares underlying"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "75.3900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"vests over 36 equal monthly installments, commencing on August 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did PTC Therapeutics (PTCT) grant to Hege Elisabeth Sollie-Zetlmayer?

PTC Therapeutics granted Hege Elisabeth Sollie-Zetlmayer 6,000 shares of common stock via restricted stock units and 5,213 shares via stock options. These awards were all granted on July 28, 2026 as part of her equity compensation package.

How do the restricted stock units for PTCT vest for Hege Elisabeth Sollie-Zetlmayer?

One RSU grant of 4,000 shares vests in three equal annual installments starting July 28, 2027. A second RSU grant of 2,000 shares vests in full on January 2, 2027, providing both long-term and near-term equity vesting schedules.

What are the terms of the stock options granted by PTCT to its director?

Sollie-Zetlmayer received stock options for 3,475 and 1,738 shares of common stock with an exercise price of $75.39 per share. Both option grants expire on July 27, 2036, giving a long exercise window.

What are the vesting schedules for the PTCT stock options granted on July 28, 2026?

The 3,475-share option grant vests over 36 equal monthly installments starting August 28, 2026. The 1,738-share option grant vests over six equal monthly installments starting August 2, 2026, creating staggered short- and medium-term vesting.

Is the PTCT Form 4 transaction a purchase or a grant for the director?

The Form 4 reports grants, not market purchases. All four transactions are coded as awards or other acquisitions (Code A), reflecting equity compensation in the form of restricted stock units and stock options, rather than open-market buying.

Does the PTCT director’s Form 4 involve any stock sales or dispositions?

No. All reported transactions are acquisitions of equity awards. The filing shows grants of restricted stock units and stock options, with no sales, gifts, or other dispositions reported for the July 28, 2026 transaction date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sollie-Zetlmayer Hege Elisabeth

(Last)(First)(Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/28/2026A(1)4,000A$050,526D
Common Stock07/28/2026A(2)2,000A$052,526D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$75.3907/28/2026A(3)3,47507/28/202607/27/2036Common Stock3,475$03,475D
Stock Option (Right to Buy)$75.3907/28/2026A(4)1,73807/28/202607/27/2036Common Stock1,738$01,738D
Explanation of Responses:
1. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027.
2. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027.
3. This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026.
4. This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026.
/s/ Avraham S. Adler, Attorney-in-Fact07/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)